Biovest

Karel Van De Woestijnestraat 3

9000 GENT

BE

Biovest

Foundation date

15/05/1996

Sector

#Investor

Subsector

Private investor.

Upcoming events

Latest news

  • argenx reports topline results from ADVANCE-SC study of VYVGART Hytrulo in primary immune thrombocytopenia

    19 hours ago

  • Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion

    Wednesday November 22nd 2023

  • argenx announces European Commission approval of subcutaneous VYVGART® (efgartigimod alfa) for generalized myasthenia gravis

    Thursday November 16th 2023